John V. Oyler

Co-Founder, Chairman & CEO of @Beonemedicines, a global oncology company built to deliver highest quality therapies to billions more people. MIT & Stanford alum

[John V. Oyler @johnvoyler]

#News for #Investors and #Media:

Proud to share BeOne’s Q1 FY2026 results. It was another solid quarter of execution that would not be possible without the hard work of our 12,000 purpose-driven colleagues around the globe.

[BeOne Medicines @BeOneMedicines]

#News for #Investors and #Media: BeOne Medicines announces first quarter 2026 financial results and business updates.

Read the full press release here: https://t.co/cWvvpLzWwd

[John V. Oyler @johnvoyler]

#News for #Investors and #Media:

Proud to share BeOne’s Q4 and full-year 2025 results. It was another solid quarter of execution and a strong finish to the year. This would not be possible without the hard work and dedication of our 12,000 colleagues around the globe.

[BeOne Medicines @BeOneMedicines]

#News for #Investors and #Media:

BeOne Medicines announces fourth quarter and full-year 2025 financial results and business updates.

Read the full press release here: https://t.co/I13RlLLmZl

[John V. Oyler @johnvoyler]

I’m looking forward to connecting with investors, partners, and stakeholders from across the global healthcare community at the J.P. Morgan Healthcare Conference this week.

On Tuesday, January 13, I’ll highlight @BeOneMedicines' transformative goal leadership and progress in treating B-cell malignancies - and share how our long-term strategy is grounded in innovation, discipline, and a deep commitment to patients.

I’ve been coming to JPM for the last 25 years – it’s always an important moment to exchange ideas, discuss the future of oncology, and engage in meaningful conversations about where healthcare is headed.

I truly believe that, together, we are how the world stops cancer. #JPM2026

[John V. Oyler @johnvoyler]

At @BeOneMedicines, we believe Cancer Has No Borders, and Neither Do We. That's why we brought nearly 100 patient advocates together at #ASH2025 for our AI Innovation Lab, to explore how AI can transform the blood cancer patient journey.

While there, we learned:

1) Patients are already turning to AI - we need to meet them there.

A story was shared about a blood cancer patient who uploaded scan results into AI before speaking to a doctor. The information received was inaccurate and almost a decade old. So, while the tools still need to improve, we can’t wait for that happen: patients are already using AI, and the broader cancer community must help them navigate it safely with trustworthy information.

2) We're witnessing a fundamental shift: patients are becoming CEOs of their own health.

Data Deloitte shared shows 51% of patients are willing to tell their doctors they disagree, up from single digits just years ago. This shift does not undermine clinical expertise - it reflects patients’ growing desire to participate actively in decisions about their care. For all of us, this means ensuring patients have clearer information and tools that help them make confident decisions with their clinicians.

3) AI + human judgment is where the real power lies.

The cancer journey is deeply human - and AI can’t change that. It’s not here to replace human judgment or compassion, but when developed responsibly and grounded in trusted data, AI can amplify human expertise, enhance decision-making, and help care teams deliver more informed, compassionate, and connected care.

What's next?

This was the first conversation of many. We're going to continue this work with patients, advocates, clinicians, and partners across the cancer community to shape AI-enabled tools that:

-- accelerate blood cancer education

-- improve data integrity and access to trusted information

-- make care more personal and human

[John V. Oyler @johnvoyler]

I’m very humbled to be named the 2025 National Health winner for the Entrepreneur Of The Year® program by EY. An entrepreneur is only as strong as their team. All success – and recognition like this - comes from their ability to help bring a vision to life. Thank you to @BeOneMedicines almost 12,000 employees and the many patients and families who have accompanied us on our journey. #EOYUS #EYSGF

[John V. Oyler @johnvoyler]

#News for #Investors and #Media:
Proud to share BeOne’s Q3 2025 results — another milestone on our path to becoming the world’s leading oncology company.

- This quarter, we delivered 41% revenue growth to $1.4B and achieved strong momentum across our portfolio

- BRUKINSA reached $1.0B in global revenue, now the global leader in the BTK inhibitor class.

- Earnings per ADS: GAAP $1.09 | Non-GAAP $2.65

- Continued progress with sonrotoclax and our degrader, BGB-16673, reinforcing our leadership in B-cell malignancies.
Nearly 50 BeOne abstracts were accepted for presentation at the upcoming ASH 2025 Annual Meeting, reflecting our deep scientific strength and commitment to delivering the best long-term outcomes for patients.

Thank you to our patients, their families, clinicians, and our 12,000 colleagues across six continents.

Together, we are how the world stops cancer – and we’re just getting started.

[BeOne Medicines @BeOneMedicines]

#News for #Investors and #Media:

BeOne Medicines announces third quarter 2025 financial results and business updates.  Read the full press release here: https://t.co/X5ui6J0Rr6

[John V. Oyler @johnvoyler]

#News for #Investors and #Media:
At #ESMO25, we are sharing the first clinical data of an investigational HKP1 inhibitor in combination with our PD-1 inhibitor. We’re proud to be advancing solid tumor research in some of the world’s deadliest cancers. #BeOneAgainstCancer #CancerResearch

[BeOne Medicines @BeOneMedicines]

#News for #Investors and #Media:

We’re at #ESMO25 with new data from across two pivotal lung cancer studies in NSCLC and ES-SCLC, plus the first clinical results for our HPK1 inhibitor in combination with our PD-1 inhibitor. We’re committed to advancing both established and investigational treatments – shaping the next generation of options for people living with lung cancer.

Read the press release: https://t.co/aafjVhcwyw

[John V. Oyler @johnvoyler]

The latest episode of The Cancer Has No Borders podcast, hosted by Zachary Randles-Friedman, features @PatGarciaGonzal, CEO and co-founder of @themaxfndn. Her organization has helped deliver lifesaving cancer therapies to more than 100,000 patients across 80+ countries. The conversation explores how partnerships like ours can expand global access to innovative medicines, strengthen healthcare infrastructure, and bring dignity and hope to patients and families in low-resource settings.

Listen to the full episode:
Apple: https://t.co/qhi8xFW4Nv

Spotify: https://t.co/NG9Wuz7xCM

YouTube: https://t.co/qODkLmHSKa

Learn more about The Max Foundation: https://t.co/0gt9786qxh

[John V. Oyler @johnvoyler]

This week, we’re honored to welcome executive leaders from across the globe to our San Carlos office. Together, at @BeOneMedicines, we are unlocking the transformative potential of AI, aligning our vision for 2026 and beyond, and deepening the culture that fuels our people.

When we gather as One Team, the momentum is undeniable. United by our mission, we're scaling faster, innovating boldly, and shaping a future where patients and communities worldwide feel the impact. Together, we are how the world stops cancer.

[John V. Oyler @johnvoyler]

Our team was honored to spotlight our partners at @BloodCancerUtd—an organization building on 76 years of impact with a bold new vision for the future.

In our latest Cancer Has No Borders podcast, Zachary Randles-Friedman had the privilege of sitting down with @LynnGodfrey3, SVP and Chief Experience Officer, to talk about:

- The rebrand from The Leukemia & Lymphoma Society to Blood Cancer United
- How research and innovation are driving progress for patients
-Their bold ambition to extend one million years of life for people with blood cancer

This conversation highlights the power of vision, partnership, and relentless focus on patient outcomes. I encourage you to listen, reflect, and join us in supporting their mission.

Link to episode:

Apple: https://t.co/YKGm2SI5PP
Spotify: https://t.co/9N4qFGqvPw
YouTube:
https://t.co/0qpDHeoiU8

[John V. Oyler @johnvoyler]

At BeOne Medicines, we are committed to advancing science for patients facing some of the most difficult cancers. Today we announced positive topline results from our Phase 2 study of our next-generation BCL2 inhibitor in relapsed/refractory mantle cell lymphoma.

This milestone reflects the determination of the patients and families who participated, the investigators who led the research, and the BeOne team that continues to drive innovation. While much work remains, we are encouraged by this progress and remain focused on addressing the urgent needs in blood cancers.

[BeOne Medicines @BeOneMedicines]

#News for #Investors and #Media: Mantle cell lymphoma (MCL) is rare, aggressive, and often diagnosed late – leaving patients with few options.

Today, we announced positive topline results for our next-generation BCL2 inhibitor in relapsed/refractory (R/R) MCL.

Explore how we’re helping to advance a potentially new path forward for MCL patients: https://t.co/ceiuPhsRGY

[John V. Oyler @johnvoyler]

New Epidsode: Cancer Has No Borders Podcast: Why is cancer mortality nearly 50% higher in parts of Eastern Europe than in Western Europe?

In our latest podcast episode, we tackle this urgent and deeply personal question—with real talk, real data, and real solutions.

- What’s behind this disparity?
- What can be done to change it?

Join Zachary Randles-Friedman, Senior Director of Digital Communications at @BeOneMedicines, in conversation with:

- Caroline Berchet, Health Economist at OECD

- Sebastian Bojkow, Head of Market Access for Sub-region Europe at BeOne Medicines

Together, they explore the systemic barriers to equitable cancer care—and the bold actions needed to break them down.

This is a conversation about equity, urgency, and hope.

Because cancer has no borders—and neither do we. At BeOne Medicines, we're building a future where access to care isn’t dictated by geography.

Listen now:
Apple: https://t.co/9k21OzB4Si

Spotify: https://t.co/yU8jCaUZHK

YouTube: https://t.co/hlBHa1fqti

hashtag#CancerCare hashtag#BeOneAgainstCancer hashtag#Collaboration hashtag#HealthEquity hashtag#PolicyMatters hashtag#InnovationInHealth

[John V. Oyler @johnvoyler]

Today, we announced our Q2 2025 earnings, continuing to build on the momentum from earlier this year.

This quarter marked another strong performance for the company, driven by the dedication and innovation of our @BeOneMedicines team.

I’m proud of the consistent progress we’re making as we deliver value for our customers and shareholders. Read the press release here: https://t.co/i3U7hB7ltX

[BeOne Medicines @BeOneMedicines]

Each year in the U.S., nearly 2 million people are diagnosed with cancer. Globally, it’s the second leading cause of death—and by 2040, cases are projected to surge to 30 million, with more than 15 million deaths. At BeOne, we’re confronting this staggering challenge head-on.

One year ago, we opened our flagship U.S. biologics manufacturing and clinical R&D facility in Hopewell, NJ—a major milestone in our mission to deliver innovative cancer medicines to more patients, faster.

@Johnvoyler, Co-Founder, Chairman and CEO, and Matt Shaulis, GM, North America, reflect on the impact Hopewell is having, and how it’s advancing our bold mission to eradicate cancer through innovation, speed, and access.

📖 Read their op-ed in @ROINJNews: https://t.co/izScRqydqc
#PatientsFirst #BeOneInnovator: https://t.co/izScRqydqc

#PatientsFirst #BeOneInnovator

[John V. Oyler @johnvoyler]

At @BeOneMedicines, we’re building a future where innovation in oncology is accessible to every patient, everywhere.

Cancer impacts millions globally, yet the most advanced treatments often remain out of reach for far too many. We’re here to change that.

From conducting clinical trials across 45+ countries to engaging patients directly in our R&D process, BeOne is rethinking every step of drug development. Our globally inclusive model isn’t just faster and more efficient—it’s more equitable.

With over 1.7 million patients reached, we’re proving that bold science and meaningful access can go hand in hand.

Read full article in Life Sciences Review to learn more about BeOne: https://t.co/UbDcGRnIkD

[John V. Oyler @johnvoyler]

In the latest episode of Cancer Has No Borders, we’re joined by Matthew Shaulis, General Manager for North America at BeOne Medicines.

Matt brings a deeply personal connection to our mission -- one that shapes how he leads and why he’s so passionate about changing the cancer care landscape. In this candid conversation, he shares how personal experience drives purpose—and how that purpose powers BeOne’s bold approach.

We also dive into BeOne’s strategic vision, from expanding global clinical trials, building impactful partnerships, and reimagining what’s possible in cancer care.

I invite you to listen on your favorite podcast platform or watch the full interview on YouTube.
#CancerHasNoBorders #OncologyInnovation #Podcast

[BeOne Medicines @BeOneMedicines]

New episode alert!

In the latest episode of the Cancer Has No Borders podcast, we’re joined by Matt Shaulis, General Manager of North America, BeOne Medicines. In this conversation, Matt shares his personal connection to BeOne’s mission, our growing R&D, clinical, and manufacturing presence across North America, the partnerships driving our efforts to transform cancer care — and more.

Listen now on your favorite podcast platform or watch the full interview on YouTube.

YouTube: https://t.co/3u4xh1TOgD
Apple: https://t.co/vIBdQ7ZYFl
Spotify: https://t.co/zvunVeHFJT

#CancerHasNoBorders #Podcast #Oncology

[John V. Oyler @johnvoyler]

I enjoyed my conversation with Yaron last week, where we explored how our unique culture—grounded in ownership and urgency—truly sets us apart. Full interview below.

[BeOne Medicines @BeOneMedicines]

Last week, @johnvoyler, Co-Founder, Chairman and CEO of BeOne sat down with Yaron Werber to talk about how navigating the complexities of leading a global biotech company comes with both significant opportunities and real-world challenges—especially in today’s dynamic landscape. John shares a candid view of the industry's future expressing confidence in BeOne’s ability to adapt and thrive in the future . Listen to the full interview here: https://t.co/pOMOGtkzsg

[John V. Oyler @johnvoyler]

Thank you, Ernst & Young for this incredible honor.

As I reflect on the past 15 years and my journey as an entrepreneur, I’m humbled by the remarkable milestones and achievements made by our team. As we take the next step in our new chapter towards becoming a diversified biotech company globally focused on oncology, our original value of #PatientsFirst is stronger than ever.

[BeOne Medicines @BeOneMedicines]

Congratulations to our Co-Founder, Chairman & CEO, @johnvoyler, on being named an Entrepreneur of the Year by Ernst & Young!

This regional award recognizes John’s visionary leadership and entrepreneurial spirit in advancing BeOne’s purpose, growth, and impact for patients around the world.

Fifteen years ago, John co-founded BeOne with a bold mission: to accelerate innovation and expand access to life-changing cancer treatments. Today, that vision lives on through the work of more than 11,000 colleagues across six continents.

In the past year alone, BeOne has advanced 13 new molecules into the clinic—and our medicines have now reached over 1.7 million patients globally.

This honor is a powerful testament to John’s unwavering commitment to transforming cancer care.

Join us in celebrating this well-deserved recognition!

#TeamBeOne

[John V. Oyler @johnvoyler]

Following BeOne’s recent redomiciliation to Switzerland, it was an honor to meet with State Secretary for Economic Affairs Helene Budliger Artieda, alongside our Board Member Anthony Hooper, Head of Government Affairs Michael Schoen, and members of our Swiss Affiliate team.

This milestone marks more than a geographical shift—it reflects our deep commitment to forging meaningful partnerships in Switzerland and reinforcing our role within the global healthcare ecosystem.

Our discussions underscored the vital importance of collaboration to address today’s most urgent healthcare challenges and to accelerate the development and delivery of life-saving cancer therapies.

We are energized by the shared vision and support from Swiss leadership and are proud to begin this next chapter.

Here’s to driving progress, strengthening alliances, and advancing our mission to transform the lives of cancer patients around the world.
#BeOneAgainstCancer #GlobalCollaboration #CancerCare #NewBeginnings #Switzerland

[BeOne Medicines @BeOneMedicines]

This week, our Co-Founder, Chairman & CEO, @johnvoyler together with a BeOne delegation, including Board Member Anthony Hooper and Head of Government Affairs Michael Schoen, had the privilege of meeting with State Secretary for Economic Affairs, Helene Budliger Artieda. This meeting marks an important step in advancing BeOne Medicines’ presence and long-term partnerships in Switzerland.

Switzerland is known for its excellence in science, policy, and global collaboration. As we embark on this next chapter, following the recent announcement of our redomiciliation, we are proud to align with the Swiss ecosystem and its commitment to excellence.

We look forward to contributing to this dynamic landscape and to expanding our impact for patients around the world through meaningful collaboration, scientific rigor, and a shared mission to transform cancer care.

#BeOneAgainstCancer #GlobalPresence #CancerCare #Switzerland #Collaboration

[John V. Oyler @johnvoyler]

This year, we’re showcasing more data than ever before, with 31 abstracts across seven disease areas – all highlighting the progress of our hematology clinical development program and our commitment to targeted therapies that raise the standard of care.

I look forward to connecting with colleagues, peers and industry partners as we come together to help shape the future of oncology through next-generation science and patient-focused innovation.

#BeOneAgainstCancer #EHA2025 #TeamBeOne